At what enterprise value was NEOGEN (ANIMAL BIOSECURITY DIVISION) acquired in 2025?

During the acquisition of NEOGEN (ANIMAL BIOSECURITY DIVISION) by KERSIA in 2025, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of NEOGEN (ANIMAL BIOSECURITY DIVISION) when it was acquired by KERSIA?

The exact EV/EBITDA multiple for NEOGEN (ANIMAL BIOSECURITY DIVISION) is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What was the revenue of NEOGEN (ANIMAL BIOSECURITY DIVISION) at the time of the deal?

The revenue of NEOGEN (ANIMAL BIOSECURITY DIVISION) at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the NEOGEN (ANIMAL BIOSECURITY DIVISION) acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NEOGEN (ANIMAL BIOSECURITY DIVISION) deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.kersia-group.com/fr-fr/blog/2025/04/22/kersia-poursuit-sa-montee-en-puissance-mondiale-avec-la-signature-dun-accord-exclusif-pour-lacquisition-de-lactivite-biosecurite-animale-de-lamericain-neogen/

← DATABASE

Home Database Healthcare & PharmaNEOGEN (ANIMAL BIOSECURITY DIVISION)

04/2025

NEOGEN (ANIMAL BIOSECURITY DIVISION) acquired by KERSIA

UNITED STATES Healthcare Services / Sterilization & Hygiene EV 100M - 350M EUR

Context

Kersia is acquiring the animal biosecurity cleaners and disinfectants business from Neogen® through an exclusive agreement. This strategic transaction marks a major entry for the French group into the North American swine and poultry markets, complementing its existing domestic presence in the ruminant sector. The acquisition is a transformative step for the group, doubling its American activity and positioning it among the top three global players in the agricultural hygiene and disinfection market. The strategy focuses on leveraging the target's extensive product registration portfolio and its three dedicated U.S. manufacturing sites to provide nationwide coverage. This deal also expands the acquirer's international footprint into 20 new countries, particularly in Central America and the Asia-Pacific region, supporting its ambition to become the undisputed global leader in animal biosecurity.

NEOGEN (ANIMAL BIOSECURITY DIVISION), which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Neogen's Animal Biosecurity Division is a major North American division specializing in cleaners and disinfectants for the animal biosecurity market. It is a key player in the swine and poultry sectors, providing specialized hygiene and water treatment solutions. With over 120 employees and an international presence in more than 50 countries—including China, Mexico, Brazil, and Australia—the business holds an extensive portfolio of product registrations and certifications. It operates two strategic manufacturing sites in the United States: one in Memphis (Tennessee), located in the heart of the poultry belt, and another in Turlock (California). The division is recognized for its high-quality biosecurity protocols and critical role in preventing contamination within the livestock industry.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
10/2025	EVOLEM	APPERTON	FRANCE	Healthcare Services	A French healthcare player specializing in the sterilization of reusable medical equipment has restructured its capital through a secondary MBO. Operating as a mission-critical infrastructure partner within the healthcare sector, the company commands high barriers to entry rooted in stringent clinical regulations and non-discretionary hospital decontamination mandates
05/2025	FIVE ARROWS	HUBLO	FRANCE	Healthcare Services	Hublo enters a new phase of its development by welcoming Five Arrows as its new lead shareholder. This transaction marks a transition from Venture Capital to Private Equity (Primary LBO). The entry of Five Arrows aims to provide Hublo with the strategic and financial resources to consolidate its leadership in France and accelerate its expansion in Europe, particularly in Germany and Northern Europe
04/2025	TRANSCARENT	ACCOLADE	UNITED STATES	Healthcare Services	Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group
07/2024	ARDIAN	MASCO GROUP	ITALY	Healthcare Services	Ardian acquired a majority stake in Masco Group from RSBG Infrastructure (the investment arm of the RAG-Stiftung). The transaction marks a new phase of international expansion for Masco, which has grown significantly through acquisitions such as Stilmas, Olsa, and BCD Engineering
05/2024	21 INVEST / OAKLEY CAPITAL INVESTMENTS	PRODUCT LIFE	FRANCE	Healthcare Services	21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest
10/2023	MOTION EQUITY PARTNERS	BANOOK	FRANCE	Healthcare Services	Motion Equity Partners acquired a majority stake in Banook Group from Turenne Sante. The transaction was structured as a growth-oriented LBO, with the management team and Turenne Sante reinvesting substantially
09/2023	CERBA HEALTHCARE	CIRION BIOPHARMA RESEARCH	CANADA	Healthcare Services	Cerba HealthCare acquired the Canadian CRO Cirion BioPharma Research to integrate it into its global clinical trial business unit, Cerba Research. This move establishes a critical operational hub in North America, allowing the group to offer seamless cross-continental support for drug development programs
09/2023	PERMIRA	ERGOMED	UNITED KINGDOM	Healthcare Services	Permira acquired Ergomed in a recommended cash offer, taking the company private from the London Stock Exchange (AIM). The transaction was driven by the thesis that Ergomed's next phase of growth—requiring significant investment in technology and international expansion (particularly in the US)—could be better executed away from the public markets
06/2023	SUPERNOVA INVEST / HEAL CAPITAL	GLEAMER	FRANCE	Healthcare Services	Gleamer raised €27 million in Series B funding to broaden its AI solution portfolio and accelerate global commercial development. The strategic plan involves expanding the software suite to include CT scans and mammography, aiming to cover 70% of radiologists' daily diagnostic needs
06/2022	ASTORG	OPEN HEALTH	UNITED STATES	Healthcare Services	Astorg has successfully completed the acquisition of OPEN Health from Amulet Capital Partners, executing a significant secondary buyout in the highly attractive healthcare services sector. Through this transaction, Astorg secures a controlling interest in a premier medical affairs and market access business, while the existing management team will continue to helm the organization

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NEOGEN (ANIMAL BIOSECURITY DIVISION) by KERSIA are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: kersia